Clinical Trial Update: A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating revumenib in combination with chemotherapy for relapsed/refractory acute leukemias has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Leukemia
• Mixed Phenotype Acute Leukemia
• Undifferentiated Leukemia

Drugs mentioned

• Revumenib (revumenib)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED